EURE_CART header image
EURE_CART header image
EURE_CART header image
MolMed S.p.A.
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel cell and gene therapy products. MolMed’s pipeline main products are Zalmoxis® (TK), a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression prophylaxis, currently in Phase III in high-risk acute leukaemia and granted a Conditional Marketing Authorisation by the European Commission; CAR-CD44v6, an immunogene therapy project potentially effective for many haematological malignancies and several epithelial tumours, acquired by San Raffaele Hospital in 2015, and currently in preclinical development.MolMed offers top-level expertise in cell and gene therapy to third parties to develop and validate projects from preclinical to Phase III trials, including scale-up and cGMP manufacturing of retroviral and lentiviral vectors and patient-specific genetically engineered CD34+ or T-cells. MolMed has two Manufacturing facilities in Milan area (one authorized and the other one expecting authorization), with over 30 GMP suites, for a combined area of over 4,800 square meter.MolMed’s in-house GMP facility, opened in 2003, is formally authorised by the Italian Medicines Agency (AIFA) for the production and release of medicinal products. All instrumentation is installed and managed by a GMP compliant Validation Master Plan with IQ, OQ and PQ qualification. MolMed GMP Solutions provides tailor-made services offering high-level expertise to develop, conduct and validate custom studies, optimize and scale up manufacturing projects, devising innovative testing procedures addressing the unique test specifications required for novel therapies. MolMed also provides assistance for scientific advice to national and international regulatory authorities, as well as support in the documentation Pre-IND, IND, IMPD and trial specific. MolMed is headquartered at the San Raffaele Biotechnology Department (DIBiT) in Milan, Italy, with an operating unit at OpenZone in Bresso (Milan, Italy). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI)s the leading scientific and technological academic institute in France devoted to biomedical research and public health, with approximately 320 departments and 6000 researchers. Inserm, which holds a portfolio of 1279 patent families (with > 25% licensed patents), ranks 1st among European academic institutions in patent filling for biomedical research.

Roles and tasks of MLM in EURE-CART

MLM is the coordinator of the project and will lead WP2 and WP9 and will further contribute to WP2, WP3, WP4, WP5 and WP8.


PhD Catia Traversari
Research Director

PhD Giuliana Vallanti
Development & Quality Control Director

MD Daniele Alberti
Medical, Regulatory Affairs & Market Access Consultant

PhD Laura Bassetto
Regulatory Affairs Director

PhD Barbara Valentinis
Research Supervisor


Newsletter Subscription

Please fill in the information of your subscription.


You have already subscribed to Newsletter Recipients and wish to update or terminate your subscription? Click here!

News Section

With the project coming to an end in June 2021, EURE-CART publishes its... Read more